Alcami Expands its Sterile Fill-Finish Capacity with Acquisition of TriPharm Services

Transaction Advances Alcami's Strategic Plan by Adding Scale in Attractive and Growing Parenteral Markets

Alcami Investors Make Additional Equity Investment Alongside Ampersand Capital Partners to Fund Expansion

News provided by

Jan 17, 2020, 11:15 ET

DURHAM, N.C., Jan. 17, 2020 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced it has acquired TriPharm Services ("TriPharm"), a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows the recently announced $17 million expansion of Alcami's sterile fill-finish facility in Charleston, South Carolina.

In conjunction with this acquisition, funds affiliated with Madison Dearborn Partners, LLC ("MDP"), Alcami's existing majority owner, made an additional equity investment to fund Alcami's growth plan and the former majority owner of TriPharm, Ampersand Capital Partners, rolled a portion of its TriPharm ownership interest into an ownership interest in Alcami.

TriPharm's facility bolsters Alcami's existing sterile fill-finish business, adding new prefilled syringe capabilities and isolator technology, while also providing incremental flexible sterile fill-finish and lyophilization capacity to meet growing industry demand. TriPharm's new manufacturing facility is expected to be operational beginning in the second half of 2020.

"Our combination with TriPharm is an important next step in the execution of Alcami's strategy to focus investments across our network to better serve rapidly growing specialized market segments," said Alcami Interim Chief Executive Officer George Van Kula. "TriPharm expands our existing capabilities and provides additional equipment lines that will allow us to better serve the fast-developing biologics market segment."

"As drug makers increasingly shift their focus toward more specialized, targeted therapeutics, and current injectable drug shortages hamper patient care, sterile fill-finish operations at proper scale are highly valued," said TriPharm Co-Founder and Chief Executive Officer Patrick D. Walsh. "Our Research Triangle Park facility is designed to address this highly specialized industry demand."

"TriPharm represents a compelling opportunity for Alcami to capitalize on building an industry-leading position in attractive and growing end-markets, as pharmaceutical and biopharmaceutical companies increasingly rely on contract development and manufacturing organizations to manage highly technical sterile fill-finish operations," said Alcami Chairman Harry Kraemer. "I look forward to working closely with the Alcami and TriPharm teams to ensure sustained growth in sterile fill-finish for Alcami."

ABOUT ALCAMI
Alcami is a world-class fully-integrated end-to-end contract development and manufacturing organization (CDMO) headquartered in North Carolina, with executive offices in Durham and Wilmington. With approximately 900 employees, Alcami helps biologics and pharmaceutical companies of all sizes navigate the complex road of delivering breakthrough therapies to patients faster, from concept to commercialization. Alcami connects its global clients with customizable and innovative solutions for API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. For more information, please visit alcaminow.com.

ABOUT TRIPHARM
TriPharm will provide a state-of-the-art isolator manufacturing environment for liquid and lyophilized vial and syringe manufacturing options to serve pharma and biotechnology clients. For more information, please visit TriPharm.com.

ABOUT MADISON DEARBORN PARTNERS
Madison Dearborn Partners, LLC ("MDP"), based in Chicago, is a leading private equity investment firm in the United States. Since MDP's formation in 1992, the firm has raised seven funds with aggregate capital of approximately $23 billion and has completed over 140 investments. MDP is currently investing out of its most recent fund, $4.4 billion MDCP Fund VII, in businesses across a broad spectrum of industries, including health care; basic industries; businesses and government software and services; financial and transaction services; and telecom, media and technology services. For more information, please visit mdcp.com.

ABOUT AMPERSAND CAPITAL PARTNERS
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. For more information, please visit ampersandcapital.com.

SOURCE Alcami Corporation